AXNX - Axonics Modulation Technologies Inc Stock Price, Fair Value and News

67.32USD-0.06 (-0.09%)Market Closed

Market Summary

USD67.32-0.06

Market Closed

-0.09%

AXNX Alerts

Big jump in Revenue (Y/Y)

Big fall in earnings (Y/Y)
Losses in recent quarter

AXNX Stock Price

View Fullscreen

AXNX RSI Chart

AXNX Valuation

Market Cap

3.4B

Price/Earnings (Trailing)

-215.56

Price/Sales (Trailing)

8.87

EV/EBITDA

-3.1K

Price/Free Cashflow

-210.89

AXNX Price/Sales (Trailing)

AXNX Profitability

EBT Margin

-3.60%

Return on Equity

-2.54%

Return on Assets

-2.22%

Free Cashflow Yield

-0.47%

AXNX Fundamentals

AXNX Revenue

Revenue (TTM)

387.1M

Rev. Growth (Yr)

29.38%

Rev. Growth (Qtr)

-16.7%

AXNX Earnings

Earnings (TTM)

-15.9M

Earnings Growth (Yr)

-106.66%

Earnings Growth (Qtr)

-389.88%

Breaking Down AXNX Revenue

Last 7 days

0.7%

Last 30 days

-0.6%

Last 90 days

-0.9%

Trailing 12 Months

20.5%

How does AXNX drawdown profile look like?

AXNX Financial Health

Current Ratio

9.96

Debt/Equity

1e-4

Debt/Cashflow

-117.65

AXNX Investor Care

Shares Dilution (1Y)

1.26%

Diluted EPS (TTM)

-0.31

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	387.1M	0	0	0
2023	295.9M	319.8M	342.6M	366.4M
2022	194.3M	217.4M	240.9M	273.7M
2021	119.6M	150.3M	161.9M	180.3M
2020	39.0M	52.8M	86.7M	111.5M
2019	2.0M	3.3M	4.4M	13.8M
2018	0	369.7K	538.3K	707.0K
2017	0	0	0	201.0K

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Axonics Modulation Technologies Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Jan 31, 2024	keese kari leigh	sold	-236,331	67.7359	-3,489	chief financial officer
Jan 31, 2024	woock john	sold	-1,076,930	67.7359	-15,899	evp, chief mktg/strtgy officer
Jan 31, 2024	cohen raymond w	sold	-2,381,660	67.7359	-35,161	chief executive officer
Jan 31, 2024	ford alfred j jr	acquired	-	-	25,500	chief commercial officer
Jan 31, 2024	noblett karen	sold	-764,603	67.7359	-11,288	chief medical officer
Jan 31, 2024	sama rinda	acquired	-	-	28,000	chief operating officer
Jan 31, 2024	keese kari leigh	acquired	-	-	6,167	chief financial officer
Jan 31, 2024	noblett karen	acquired	-	-	27,500	chief medical officer
Jan 31, 2024	woock john	acquired	-	-	28,000	evp, chief mktg/strtgy officer
Jan 31, 2024	ford alfred j jr	sold	-1,125,430	67.7359	-16,615	chief commercial officer

Which funds bought or sold AXNX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 07, 2024	Lisanti Capital Growth, LLC	sold off	-100	-6,655,500	-	-%
May 07, 2024	ClariVest Asset Management LLC	sold off	-100	-1,832,420	-	-%
May 07, 2024	Swiss National Bank	added	0.6	711,338	6,897,000	-%
May 07, 2024	Arizona State Retirement System	reduced	-1.3	82,453	960,269	0.01%
May 07, 2024	NEW YORK STATE COMMON RETIREMENT FUND	reduced	-86.53	-8,398,000	1,475,000	-%
May 07, 2024	Headlands Technologies LLC	added	31.1	24,019	77,039	0.02%
May 07, 2024	QRG CAPITAL MANAGEMENT, INC.	new	-	828,330	828,330	0.01%
May 07, 2024	SUSQUEHANNA INTERNATIONAL GROUP, LLP	reduced	-81.05	-828,894	220,428	-%
May 07, 2024	O'Dell Group, LLC	sold off	-100	-18,856	-	-%
May 07, 2024	SEI INVESTMENTS CO	reduced	-68.18	-4,253,580	2,317,220	-%

Are Funds Buying or Selling AXNX?

Are funds buying AXNX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own AXNX

No. of Funds

Unveiling Axonics Modulation Technologies Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	vanguard group inc	10.38%	5,260,830	SC 13G/A
Feb 12, 2024	fmr llc	-	0	SC 13G/A
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Jan 25, 2024	blackrock inc.	8.3%	4,189,817	SC 13G/A
Dec 11, 2023	fmr llc	-	0	SC 13G/A
Mar 10, 2023	vanguard group inc	10.28%	5,092,888	SC 13G/A
Feb 09, 2023	fmr llc	-	0	SC 13G/A
Feb 09, 2023	vanguard group inc	9.82%	4,863,283	SC 13G/A
Jan 31, 2023	blackrock inc.	7.3%	3,630,843	SC 13G/A
Jun 06, 2022	cooperatieve gilde healthcare iv u.a.	0%	0	SC 13G/A

Recent SEC filings of Axonics Modulation Technologies Inc

View All Filings

Date Filed	Form Type	Document
Apr 30, 2024	10-Q	Quarterly Report
Apr 30, 2024	8-K	Current Report
Apr 29, 2024	10-K/A	Annual Report
Apr 04, 2024	8-K	Current Report
Mar 25, 2024	8-K	Current Report
Mar 07, 2024	DEFA14A	DEFA14A
Feb 29, 2024	10-K	Annual Report
Feb 28, 2024	8-K	Current Report
Feb 22, 2024	DEFM14A	DEFM14A
Feb 13, 2024	SC 13G/A	Major Ownership Report

Peers (Alternatives to Axonics Modulation Technologies Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	182.6B	40.3B	-5.05%	-4.82%	32.45	4.53	-2.84%	-3.08%
BDX	67.4B	19.7B	-3.45%	-6.52%	50.6	3.42	4.82%	-17.56%
ALGN	20.6B	3.9B	-14.54%	-9.65%	44.54	5.26	5.72%	46.72%
BAX	18.2B	14.9B	-15.38%	-17.01%	6.88	1.22	2.98%	207.68%
MID-CAP
ATR	10.0B	3.5B	7.32%	25.05%	31.94	2.82	6.16%	35.06%
HSIC	9.3B	12.5B	0.39%	-2.78%	24.01	0.75	-0.61%	-18.83%
BIO	7.6B	2.6B	-17.82%	-26.90%	-23.72	2.94	-6.25%	-68.62%
XRAY	5.8B	3.9B	-13.74%	-32.04%	-61.76	1.47	0.23%	91.03%
AXNX	3.4B	387.1M	-0.59%	20.47%	-215.56	8.87	30.82%	65.57%
PDCO	2.3B	6.6B	-1.26%	-0.69%	11.98	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	-6.92%	-14.34%	-1.85	0.4	7.94%	-1661.78%
ANIK	422.2M	169.3M	11.74%	12.93%	-5.49	2.49	7.49%	-244.90%
ANGO	235.9M	324.0M	-10.59%	-34.33%	-1.23	0.73	-3.19%	-337.41%
APYX	46.8M	52.3M	-10.27%	-60.90%	-2.5	0.89	17.61%	19.28%
AEMD	3.3M	3.7M	-25.00%	250.00%	-0.27	0.87	5.77%	8.23%

Axonics Modulation Technologies Inc News

Latest updates

Axonics Modulation Technologies Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-16.7%	91,409,000	109,735,000	93,100,000	92,894,000	70,650,000	85,918,000	70,384,000	68,980,000	48,420,000	53,135,000	46,913,000	45,869,000	34,373,000	34,783,000	35,243,000	15,213,000	26,296,000	9,946,000	1,309,000	1,488,000	1,077,000
Gross Profit	-16.3%	69,253,000	82,760,000	69,104,000	70,190,000	52,500,000	62,967,000	51,260,000	50,196,000	33,242,000	35,391,000	31,194,000	28,734,000	20,399,000	22,131,000	21,809,000	6,750,000	16,401,000	5,408,000	677,000	716,000	529,000
Operating Expenses	8.2%	88,432,000	81,694,000	69,791,000	82,260,000	66,866,000	66,576,000	67,635,000	71,625,000	56,775,000	53,071,000	47,696,000	44,744,000	42,015,000	33,012,000	30,578,000	26,155,000	31,106,000	28,071,000	25,724,000	19,986,000	14,148,000
S&GA Expenses	2.0%	56,191,000	55,094,000	47,544,000	44,270,000	42,654,000	43,824,000	39,751,000	39,381,000	33,063,000	31,338,000	28,112,000	25,411,000	20,928,000	18,284,000	17,057,000	14,220,000	16,569,000	16,301,000	15,707,000	10,750,000	5,914,000
R&D Expenses	13.8%	11,056,000	9,714,000	8,167,000	8,949,000	8,056,000	8,103,000	7,936,000	7,135,000	11,236,000	10,182,000	8,648,000	9,098,000	9,369,000	8,111,000	7,719,000	6,370,000	6,855,000	6,118,000	4,855,000	4,874,000	4,219,000
EBITDA Margin	-125.5%	0.00	0.01	-0.01	-0.07	-0.13	-0.18	-0.28	-0.32	-0.34	-0.38	-0.39	-0.39	-	-	-	-	-	-	-	-	-
Interest Expenses	-100.0%	-	14,000	16,000	39,000	-	-	-	-	1,000	-	1,000	2,007,000	170,000	253,000	256,000	264,000	329,000	339,000	367,000	370,000	360,000
Income Taxes	444.1%	3,847,000	-1,118,000	-427,000	-304,000	-807,000	-522,000	-520,000	-465,000	-1,111,000	-2,487,000	528,000	3,296,000	-555,000	-	-	-	1,000	-	-	1,000	-
Earnings Before Taxes	-379.8%	-15,265,000	5,456,000	3,501,000	-7,646,000	-10,055,000	143,000	-16,772,000	-21,908,000	-23,779,000	-17,653,000	-16,722,000	-21,852,000	-23,058,000	-11,348,000	-9,168,000	-19,783,000	-14,615,000	-22,751,000	-25,006,000	-19,060,000	-13,117,000
EBT Margin	-51.0%	-0.04	-0.02	-0.04	-0.11	-0.16	-0.23	-0.33	-0.37	-0.41	-0.44	-0.45	-0.44	-	-	-	-	-	-	-	-	-
Net Income	-389.9%	-19,112,000	6,593,000	3,928,000	-7,342,000	-9,248,000	665,000	-16,252,000	-21,443,000	-22,668,000	-15,166,500	-17,250,000	-25,148,000	-22,503,000	-11,348,000	-9,168,000	-19,783,000	-14,616,000	-22,751,000	-25,006,000	-19,061,000	-13,117,000
Net Income Margin	-148.3%	-0.04	-0.02	-0.04	-0.10	-0.16	-0.22	-0.31	-0.35	-0.41	-0.44	-0.47	-0.45	-	-	-	-	-	-	-	-	-
Free Cashflow	-384.4%	-12,295,000	4,323,000	11,151,000	-19,465,000	-1,575,000	9,018,000	2,884,000	-1,476,000	-9,458,000	-7,860,000	-3,678,000	-12,323,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-0.6%	716	720	661	649	666	659	632	514	526	548	561	566	445	342	348	349	217	220	126	146	159
Current Assets	-1.9%	482	491	475	455	470	465	449	313	307	321	330	332	228	328	334	336	204	212	118	138	153
Cash Equivalents	122.0%	233	105	147	145	240	239	241	203	213	221	229	231	131	241	269	288	160	171	76.00	83.00	89.00
Inventory	16.6%	93.00	80.00	75.00	70.00	66.00	56.00	58.00	58.00	62.00	65.00	70.00	70.00	71.00	63.00	44.00	30.00	19.00	16.00	13.00	8.00	5.00
Net PPE	-	-	-	7.00	6.00	7.00	7.00	7.00	7.00	7.00	7.00	6.00	6.00	6.00	6.00	6.00	6.00	5.00	3.00	3.00	3.00	3.00
Goodwill	-0.9%	99.00	99.00	95.00	99.00	97.00	94.00	87.00	95.00	103	106	110	107	87.00	-	-	-	-	-	-	-	-
Liabilities	7.4%	88.00	82.00	50.00	48.00	89.00	89.00	83.00	76.00	62.00	66.00	71.00	61.00	115	55.00	54.00	51.00	45.00	37.00	34.00	32.00	28.00
Current Liabilities	5.6%	48.00	46.00	36.00	32.00	66.00	65.00	61.00	30.00	26.00	27.00	28.00	24.00	24.00	46.00	39.00	31.00	20.00	12.00	16.00	11.00	7.00
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	0.00	75.00	-	6.00	11.00	16.00	20.00	14.00	16.00	18.00
LT Debt, Current	-	-	-	-	-	-	-	-	-	-	-	0.00	0.00	0.00	21.00	15.00	10.00	5.00	-	6.00	4.00	2.00
LT Debt, Non Current	-	-	-	-	-	-	-	-	-	-	-	-	0.00	75.00	-	6.00	11.00	16.00	20.00	14.00	16.00	18.00
Shareholder's Equity	-1.6%	627	638	611	601	577	570	550	438	463	482	490	504	330	287	294	298	172	183	92.00	114	131
Retained Earnings	-5.0%	-399	-380	-386	-390	-383	-374	-374	-358	-337	-314	-299	-282	-257	-234	-223	-213	-194	-179	-156	-131	-112
Additional Paid-In Capital	0.9%	1,044	1,034	1,022	1,010	982	970	961	821	812	804	796	788	590	522	518	513	367	363	250	247	245
Shares Outstanding	0.5%	51.00	51.00	51.00	50.00	49.00	50.00	47.00	45.00	45.00	43.00	42.00	41.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	2,500	-	-	-	2,647	-	-	-	2,893	-	-	-	1,136	-	-	-	633	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-264.0%	-9,236	5,630	12,344	-19,209	-781	9,353	3,847	-842	-9,167	-6,776	-2,994	-11,953	-25,583	-28,314	-19,146	-12,975	-23,307	-28,136	-23,904	-18,359	-13,055
Share Based Compensation	-14.3%	9,551	11,148	11,470	11,204	10,714	8,757	8,218	7,905	7,138	6,844	6,690	6,327	5,303	3,582	3,775	3,816	3,922	2,921	2,782	1,875	1,142
Cashflow From Investing	464.5%	138,232	-37,922	-11,053	-68,623	694	-10,030	-99,401	-10,632	-291	-1,084	-684	-370	-140,864	-1,023	-648	-553	11,878	12,342	17,456	11,440	4,049
Cashflow From Financing	-57.1%	248	578	878	-6,766	1,930	161	131,883	480	1,444	202	1,523	112,573	56,215	1,055	1,296	141,495	344	110,492	111	308	44.00

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

AXNX Income Statement

2024-03-31

Condensed Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Statement of Comprehensive Income [Abstract]
Net revenue	$ 91,409	$ 70,650
Cost of goods sold	22,156	18,150
Gross profit	69,253	52,500
Operating expenses
Research and development	11,056	8,056
General and administrative	15,104	12,168
Sales and marketing	56,191	42,654
Amortization of intangible assets	2,254	2,222
Acquisition-related costs	3,827	1,766
Total operating expenses	88,432	66,866
Loss from operations	(19,179)	(14,366)
Other income (expense)
Interest and other income	3,973	3,628
Interest and other expense	(59)	683
Other income, net	3,914	4,311
Loss before income tax expense (benefit)	(15,265)	(10,055)
Income tax expense (benefit)	3,847	(807)
Net loss	(19,112)	(9,248)
Foreign currency translation adjustment	(1,152)	3,071
Comprehensive loss	$ (20,264)	$ (6,177)
Net loss per share, basic (in USD per share)	$ (0.38)	$ (0.19)
Net loss per share, diluted (in USD per share)	$ (0.38)	$ (0.19)
Weighted-average shares used to compute basic net loss per share (in shares)	50,928,171	48,579,084
Weighted-average shares used to compute diluted net loss per share (in shares)	50,928,171	48,579,084

AXNX Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets
Cash and cash equivalents	$ 232,645	$ 104,811
Short-term investments	100,161	240,149
Accounts receivable, net of allowance for credit losses of $1,079 and $442 at March 31, 2024 and December 31, 2023, respectively	50,529	57,243
Inventory, net	93,187	79,940
Prepaid expenses and other current assets	5,508	9,279
Total current assets	482,030	491,422
Restricted cash	15,826	12,714
Property and equipment, net	17,037	10,760
Intangible assets, net	78,422	81,375
Other assets	23,703	24,235
Goodwill	98,543	99,417
Total assets	715,561	719,923
Current liabilities
Accounts payable	15,770	18,452
Accrued liabilities	14,752	10,527
Accrued compensation and benefits	16,409	15,060
Operating lease liabilities, current portion	1,456	1,777
Total current liabilities	48,387	45,816
Operating lease liabilities, net of current portion	30,154	25,840
Deferred tax liabilities, net	9,921	10,703
Total liabilities	88,462	82,359
Commitments and contingencies (Note 3)
Stockholders’ equity
Preferred stock, par value $0.0001 per share; 10,000,000 shares authorized, no shares issued and outstanding at March 31, 2024 and December 31, 2023	0	0
Common stock, par value $0.0001, 75,000,000 shares authorized at March 31, 2024 and December 31, 2023; 51,018,179 and 50,770,520 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	5	5
Additional paid-in capital	1,043,577	1,033,778
Accumulated deficit	(399,464)	(380,352)
Accumulated other comprehensive loss	(17,019)	(15,867)
Total stockholders’ equity	627,099	637,564
Total liabilities and stockholders’ equity	$ 715,561	$ 719,923

About Axonics Modulation Technologies Inc

Axonics, Inc., a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of bladder and bowel dysfunction. reduce the symptoms of OAB, UR, and FI. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct sales force and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is based in Irvine, California.

CEO	Mr. Raymond W. Cohen
WEBSITE	axonics.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	610

Axonics Modulation Technologies Inc Frequently Asked Questions

What is the ticker symbol for Axonics Modulation Technologies Inc? What does AXNX stand for in stocks?

AXNX is the stock ticker symbol of Axonics Modulation Technologies Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Axonics Modulation Technologies Inc (AXNX)?

As of Wed May 08 2024, market cap of Axonics Modulation Technologies Inc is 3.43 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AXNX stock?

You can check AXNX's fair value in chart for subscribers.

What is the fair value of AXNX stock?

You can check AXNX's fair value in chart for subscribers. The fair value of Axonics Modulation Technologies Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Axonics Modulation Technologies Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for AXNX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Axonics Modulation Technologies Inc a good stock to buy?

The fair value guage provides a quick view whether AXNX is over valued or under valued. Whether Axonics Modulation Technologies Inc is cheap or expensive depends on the assumptions which impact Axonics Modulation Technologies Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AXNX.

What is Axonics Modulation Technologies Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed May 08 2024, AXNX's PE ratio (Price to Earnings) is -215.56 and Price to Sales (PS) ratio is 8.87. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AXNX PE ratio will change depending on the future growth rate expectations of investors.